Elixir Taps Chief Medical Officer

Elixir Pharmaceuticals Inc. said Thursday Paul M. Martha, M.D. has been named to the newly-created position of chief medical officer.

Cambridge, Mass.-based Elixir said Martha will be responsible for managing the clinical development of Elixir's product candidates. Martha will be focused initially on overseeing the Phase III program for Glinsuna and Metgluna, which are being developed for the treatment of Type 2 diabetes, as well advancing the ghrelin antagonist, ghrelin agonist and SIRT programs through clinical development.

Martha was previously at Interleukin Genetics as chief medical and regulatory officer and at Praecis Pharmaceuticals as vice president, clinical research and development, and at Genentech Inc.

All contents of this site © American City Business Journals Inc. All rights reserved.